North America Breast Cancer Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Therapy, Breast Cancer Type, and Distribution Channel

The North America breast cancer therapeutics market was valued at US$ 13,346.87 million in 2022 and is expected to reach US$ 27,014.92 million by 2030; it is estimated to grow at a CAGR of 9.2% from 2022 to 2030.

Increasing Use of Personalized Medicine Fuels the North America Breast Cancer Therapeutics Market

Personalized medicine involves tailoring treatment plans to individual patients on the basis of their genetic makeup, among other factors. This approach allows for highly targeted and effective treatments, as it considers the unique characteristics of each patients cancer. Advancements in genomics and molecular diagnostics have made personalized medicine a viable option in breast cancer treatment. Healthcare providers can identify specific genetic mutations or biomarkers driving the cancers growth by analyzing a patients tumor at a molecular level. This information can then be used to select the most appropriate treatment options, such as targeted therapies or immunotherapies, that are likely to be the most effective for that particular patient. The use of personalized medicine in breast cancer therapeutics has the potential to significantly improve patient outcomes. For instance, in February 2022, NIH researchers developed a personalized breast cancer therapy approach, an experimental form of immunotherapy that uses a patients tumor-fighting immune cells to treat those with metastatic breast cancer, advancing personalized medicine.

By providing tailored treatments to individual patients, healthcare providers can increase the likelihood of successful outcomes and reduce the risk of unnecessary side effects. In addition to improving patient outcomes, personalized medicine also offers economic benefits. By selecting treatments that are more likely to be effective, healthcare providers can reduce healthcare costs associated with ineffective treatments and avoid unnecessary expenses. As advancements in genomics and molecular diagnostics progress, personalized medicine is likely to become increasingly accessible and integrated into standard treatment protocols in the coming years. Therefore, the increasing use of personalized medicine is anticipated to bring new growth trends in the North America breast cancer therapeutics market.

North America Breast Cancer Therapeutics Market Overview

The breast cancer therapeutics market in North America is segmented into the US, Canada, and Mexico; the US holds the largest market share in this region. The market growth is mainly attributed to the region, which is expected to witness consistent growth owing to factors such as the rising prevalence of breast cancer and rising R&D investments for developing novel treatments. In addition, a growing number of market players are expanding their geographical footprint in North American countries.

Improvements in medical technology and research have sparked the creation of ground-breaking treatments that can enhance patient outcomes. Several large pharmaceutical companies, including Pfizer, Novartis, Roche, AstraZeneca, and Eli Lilly, dominate the therapeutic market for breast cancer in the US. These businesses make significant investments in research and development to introduce novel and enhanced medicines to the market. Regulations and policies put in place by the government also affect the market. New medications and therapies for breast cancer treatment are approved by the government agencies of the Food and Drug Administration (FDA). In the upcoming years, the therapeutic market for breast cancer is anticipated to expand further.

North America Breast Cancer Therapeutics Market Segmentation

The North America breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.

Based on drug therapy, the North America breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.

In terms of breast cancer type, the North America breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.

By distribution channel, the North America breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.

Based on country, the North America breast cancer therapeutics market is categorized into US, Canada, and Mexico. The US dominated the North America breast cancer therapeutics market in 2022.

Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Genentech Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are some of the leading companies operating in the North America breast cancer therapeutics market.